Adjuvant interferon alfa for melanoma.
作者信息
Wilson Kenneth S, Attwell Andrew
出版信息
Curr Oncol. 2010 Jun;17(3):6-7. doi: 10.3747/co.v17i3.511.
Abstract
摘要
相似文献
1
Adjuvant interferon alfa for melanoma.黑色素瘤的辅助性干扰素α治疗
Curr Oncol. 2010 Jun;17(3):6-7. doi: 10.3747/co.v17i3.511.
2
The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.辅助性α-干扰素治疗在已切除高危黑色素瘤不断发展的治疗格局中的疗效与安全性。
Expert Opin Drug Saf. 2017 Aug;16(8):933-940. doi: 10.1080/14740338.2017.1343301. Epub 2017 Jun 30.
3
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.高危黑色素瘤患者采用中剂量干扰素 alfa-2b 进行两种不同持续时间的辅助治疗（北欧 IFN 试验）：一项随机 3 期试验。
Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20.
4
Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.制定黑色素瘤前哨淋巴结活检及辅助使用高剂量干扰素α-2b的适应证。
Arch Dermatol. 2001 Sep;137(9):1217-24. doi: 10.1001/archderm.137.9.1217.
5
6
Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.辅助性干扰素治疗高危转移性葡萄膜黑色素瘤患者。
Ophthalmology. 2009 Nov;116(11):2206-12. doi: 10.1016/j.ophtha.2009.04.044. Epub 2009 Sep 10.
7
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.在无巨淋巴结转移的黑色素瘤患者中，聚乙二醇干扰素 alfa-2b（36 个月）辅助治疗对比低剂量干扰素 alfa-2b（18 个月）：一项开放标签、随机、III 期欧洲皮肤病肿瘤学会（EADO）研究。
Eur J Cancer. 2013 Jan;49(1):166-74. doi: 10.1016/j.ejca.2012.07.018. Epub 2012 Sep 10.
8
Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.前瞻性、随机、多中心、双盲安慰剂对照试验：比较辅助性干扰素α联合异维A酸与单用干扰素α治疗IIA期和IIB期黑色素瘤的疗效——欧洲黑色素瘤辅助治疗协作研究组
J Clin Oncol. 2005 Dec 1;23(34):8655-63. doi: 10.1200/JCO.2004.00.8128. Epub 2005 Oct 31.
9
[Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].干扰素α-2b辅助治疗葡萄膜黑色素瘤的安全性和有效性
Ophthalmologe. 2006 Jun;103(6):506-11. doi: 10.1007/s00347-006-1350-7.
10
The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.干扰素α作为晚期皮肤黑色素瘤辅助治疗的应用：需要更多证据。
J Am Acad Dermatol. 2000 Oct;43(4):708-11. doi: 10.1067/mjd.2000.107500.
本文引用的文献
1
Adjuvant interferon in high-risk melanoma: end of the era?高危黑色素瘤的辅助性干扰素：时代终结？
J Clin Oncol. 2010 Jan 10;28(2):e15-6; author reply e17-8. doi: 10.1200/JCO.2009.24.9326. Epub 2009 Nov 30.
2
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.切除高危黑色素瘤患者辅助性高剂量干扰素α-2b治疗1个月与1年的随机III期研究。
J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12.
3
High-dose interferon versus GM2 vaccine in high-risk malignant melanoma.高剂量干扰素与GM2疫苗治疗高危恶性黑色素瘤的对比研究
J Clin Oncol. 2001 Dec 1;19(23):4350.
4
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.高剂量和低剂量干扰素α-2b治疗高危黑色素瘤：E1690/S9111/C9190组间试验的首次分析
J Clin Oncol. 2000 Jun;18(12):2444-58. doi: 10.1200/JCO.2000.18.12.2444.
Zotero 插件